Solution oral Alfakholin is nazanachat at the following indications:

• Psychoorganic syndrome against the background of involutional and degenerative processes in a brain, consequences of cerebrovascular insufficiency or primary and secondary cognitive disturbances at elderly people which are characterized by memory disturbance, confusion of consciousness, a disorientation, decrease in motivation and initiative, decline in the ability to concentration of attention.
• Behavior disorder and affective sphere at people of advanced age: emotional lability, acrimony, indifference to the world around, pseudo-melancholy.

Structure

Active ingredient: choline alfoscerate;

7 ml of medicament sincaline of the alfostserat;

Excipients: methylparahydroxybenzoate (E 218), propilparagidroksibenzoat (E 216), sodium saccharin, Orange fragrance, the water purified.

Contraindication

• Hypersensitivity to medicine components.
• Period of pregnancy and feeding by a breast.
• Age of the patient up to 18 years (due to the lack of data).
• Significant psychomotor excitement at patients with psychotic disorders.

to Accept

on 1 bottle of solution oral 2 once a day.

Specified dose can be increased by the doctor.

to

Pregnant

Medicine is contraindicated to

Feature of use

Children

Experience of use to children is absent.

Drivers

Should be careful at control of motor transport or other types of activity demanding the increased concentration of attention and/or speed of reaction.

strengthening of expressiveness of dose-dependent side effects Is possible

. The overdose can be shown by nausea, concern, excitement, insomnia. Symptomatic treatment: intake of the adsorbing medicines, including intake of activated carbon. The efficiency of dialysis is not established.

Side effects

As a rule, medicine is good to be transferred even at prolonged use.

In an initiation of treatment such manifestations of side reactions can arise: alarm, agitation, insomnia. These symptoms passing also do not demand the treatment termination, but perhaps temporary dose decline.

from digestive tract: nausea (which, mainly, is a consequence of secondary dopaminergic activation), abdominal pain.

from nervous system: short-term confusion of consciousness (in this case it is necessary to reduce a dose), a headache.

from a cardiovascular system: lowering of arterial pressure.

from the immune system: reactions of hypersensitivity: erubescence, rash, itching, urticaria, Quincke's disease.

by

.

Storage conditions

to Store

in original packing at a temperature not above 25 °C. Not to freeze.

to Store

out of children's reach.

Expiration date - 1.5 years.